Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05634967 · ClinicalTrials.gov registry record

Kesimpta (Ofatumumab) Pregnancy Registry

A clinical trial of Multiple Sclerosis and Pregnancy, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
725
Enrollment target
1
Study location

NCT05634967 is a study of Multiple Sclerosis and Pregnancy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 725 participants, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05634967, a study of Multiple Sclerosis and Pregnancy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
725 participants
Enrollment target
1
Study location

Study Summary

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

Interventions

  • OTHER Kesimpta

Study Locations (1)

California

  • University of California San Diego OTIS - La Jolla

Trial Details

FieldValue
Enrollment Target 725 participants
Start Date 2023-01-05
Est. Completion 2033-02-28

Sponsor

Novartis Pharmaceuticals

1,375 total trials

What the Registry Record Tells You About NCT05634967

The ClinicalTrials.gov registry entry for NCT05634967 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 725 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (24% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Kesimpta is the first listed.

NCT05634967 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05634967 about?

NCT05634967 is a clinical study titled "Kesimpta (Ofatumumab) Pregnancy Registry". The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

What is the current status of trial NCT05634967?

This trial is currently recruiting. The enrollment target is 725 participants. The study started on 2023-01-05. Estimated completion is 2033-02-28.

What conditions does trial NCT05634967 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Pregnancy.

What interventions are being tested in trial NCT05634967?

The interventions under investigation include: Kesimpta (OTHER).

Who is sponsoring clinical trial NCT05634967?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05634967 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.